Biologic drugs in noninfectious uveitis: an update

References

• Reeves SW, Sloan FA, Lee PP, Jaffe GJ. Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology 113, 307 e1 (2006).
   PubMedGoogle Scholar
• Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 26, 17–28 (2012).
   PubMed Web of Science ®Google Scholar
• Lyon F, Gale RP, Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin. Investig. Drugs 18, 609–616 (2009).
   PubMed Web of Science ®Google Scholar
• McDermott MF. TNF and TNFR biology in health and disease. Cell. Mol. Biol. 47, 619–635 (2001).
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye Res. 23(6), 617–637 (2004).
   PubMed Web of Science ®Google Scholar
• Khera TK, Dick AD, Nicholson LB. Mechanisms of TNF-a regulation in uveitis: focus on RNA-binding proteins. Prog. Retin. Eye Res. 29(6), 610–621 (2010).
   PubMedGoogle Scholar
• Hamzaoui K, Hamzaoui A, Guemira F et al. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand. J. Rheumatol. 31, 205–210 (2002).
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Struyf S, Kangave D et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin. Immunol. 139, 177–184 (2011).
   PubMed Web of Science ®Google Scholar
• Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behçet uveitis. Am. J. Ophthalmol. 142, 429–434 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M et al. Tumor necrosis factor-alpha levels in aqueous humor and serum for patients with uveitis: the involvement of HLA-B27. Curr. Med. Res. Opin. 20, 155–157 (2004).
   PubMed Web of Science ®Google Scholar
• Dick AD, McMenamin PG, Körner H et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur. J. Immunol. 26, 1018–1025 (1996).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleiscmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Zink A et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8), 1407–1415 (2012).
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 121(4), 437–440 (2003).
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113, 2317–2323 (2006).
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr. Eye Res. 35, 751–756 (2010).
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J. Rheumatol. 39(2), 233–239 (2012).
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Artaraz J, Les I et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul. Immunol. Inflamm. 20(1), 44–48 (2012).
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Berthelot JM et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin. Arthritis Rheum. 41(3), 503–510 (2011).
   PubMed Web of Science ®Google Scholar
• Smolen JS and Emery P. Infliximab: 12 years of experience. Arthritis Res. Ther. 13(Suppl. 1), S2 (2011).
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S et al. Induction of regulatory T cells by infliximab in Behçet’s disease. Invest. Ophthalmol. Vis. Sci. 52, 476–484 (2011).
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J. Rheumatol. 40(1), 74–79 (2013).
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol. 127(6), 819–822 (2009).
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Gevorgyan O, Payal A, Siddique SS, Foster CS. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology 120(3), 588–592 (2012).
   PubMedGoogle Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J et al. Tumor necrosis factor alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 34, 1146–1150 (2007).
   PubMed Web of Science ®Google Scholar
• Adan A, Sanmarti R, Bures A, Casaroli-Marano RP. Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome. Am. J. Ophthalmol. 143, 533–534 (2007).
   PubMed Web of Science ®Google Scholar
• Russell E, Luk F, Manocha S, Ho T, O’Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin. Arthritis Rheum. 43(1), 119–124 (2013).
   PubMed Web of Science ®Google Scholar
• Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch. Ophthalmol. 129, 250–252 (2011).
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 52, 2478–2484 (2005).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br. J. Ophthalmol. 94,284–288 (2010).
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin. Arthritis Rheum. 41(1), 61–70 (2011).
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behçet’s Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch. Ophthalmol. 130(5), 592–598 (2012).
   PubMed Web of Science ®Google Scholar
• Handa T, Tsunekawa H, Yoneda M et al. Long-term remission of ocular and extraocular manifestations in Behçet’s disease using infliximab. Clin. Exp. Rheumatol. 29 (4 Suppl. 67), S58–S63 (2011).
   PubMed Web of Science ®Google Scholar
• Lee RW, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet’suveitis. Br. J. Ophthalmol. 94(3), 269–270 (2010).
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50, 593–597 (2011).
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 46(7), 1161–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Adán A, Hernandez V, Ortiz S et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. Int. Ophthalmol. 30(5), 577–581 (2010).
   PubMedGoogle Scholar
• Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J. Ocul. Pharmacol. Ther. 28(6), 628–631 (2012).
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am. J. Ophthalmol. 154(3), 534–541 e1 (2012).
   PubMed Web of Science ®Google Scholar
• Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas. J. Dermatol. doi:10.1111/ajd.12054 (2013) (Epub ahead of print).
   PubMedGoogle Scholar
• Hanson RL, Gannon MJ, Khamo N, Sodhi M, Orr AM, Stubbings J. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty. J. Manag. Care. Pharm. 19(1), 49–67 (2013).
   PubMedGoogle Scholar
• Seror R, Richez C, Sordet C et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 52(5), 868–874 (2013).
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Chen L, Fraunfelder FW et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic therapy (SABER) Study. Am. J. Ophthalmol. 155(1), 183–189 e1 (2013).
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP et al. Overall and cancer related mortality among patients with immunosuppressive drugs: retrospective cohort study. BMJ 339, b2480 (2009).
   PubMedGoogle Scholar
• Brown SL, Greene MH, Gershon SK et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46, 3151–3158 (2002).
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.Br. J. Ophthalmol. 97(4), 481–486 (2013).
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br. J. Ophthalmol. 97(2), 134–138 (2013).
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 250(5), 713–720 (2012).
   PubMed Web of Science ®Google Scholar
• Sen ES, Sharma S, Hinchcliffe A, Dick AD, Ramanan AV. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study. Rheumatology (Oxford). 51(12), 2199–2203 (2012).
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL et al. Adalimumab for the treatment of Behcet’s disease: experience in 19 patients. Rheumatology (Oxford). 51(10), 1825–1831 (2012).
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8), 1575–1581 (2012).
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr. Rheumatol. Online J. 11(1), 16 (2013).
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul. Immunol. Inflamm. 21(1), 19–27 (2013)
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Landewé RB et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann. Rheum. Dis. 71(10), 1671–1679 (2012).
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M et al. Golimumab for uveitis. Ophthalmology 118, e3–e4 (2011).
   PubMedGoogle Scholar
• William M, Faez S, Papaliodis GN et al. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J. Ophthalmic. Inflamm. Infect. 2(4), 231–233 (2012).
   PubMedGoogle Scholar
• Mesquida M, Victoria Hernández M, Llorenç V et al. Behçet Disease-associated Uveitis Successfully Treated with Golimumab. Ocul. Immunol. Inflamm. 21(2), 160–162 (2012).
   PubMed Web of Science ®Google Scholar
• Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 73(1), 75–97 (2013).
   PubMedGoogle Scholar
• Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn’s disease. Expert Opin. Biol. Ther. 13(4), 595–605 (2013).
   PubMed Web of Science ®Google Scholar
• Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNF alpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul. Immunol. Inflamm. 17(6), 403–414 (2009).
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 23(9), 1868–1870 (2009).
   PubMed Web of Science ®Google Scholar
• Furuta S, Chow YW, Chaudhry AN, Jayne D. Switching of anti-TNF-a agents in Behçet’s disease. Clin. Exp. Rheumatol. 30(3 Suppl. 72), S62–68 (2012).
   Google Scholar
• Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132(4), 466–474 (2011).
   PubMedGoogle Scholar
• Deuter C, Stübiger N, Zierhut M. Interferon-a therapy in noninfectious uveitis. Dev. Ophthalmol. 51, 90–97 (2012).
   PubMedGoogle Scholar
• Gueudry J, Wechsler B, Terrada C et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am. J. Ophthalmol. 146(6), 837–844 e1 (2008).
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br. J. Ophthalmol. 91(3), 335–339 (2007).
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch. Dermatol. Res. 278(4), 335–336 (1986).
   PubMed Web of Science ®Google Scholar
• Kötter I. Management of Behçet’s disease: a systematic literature review for the European League Against Rheumatism evidence-base recommendations for the management of Behçet’s disease. Z. Rheumatol. 69(7), 658–659 (2010).
   PubMedGoogle Scholar
• Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 62(9), 2796–2805 (2010).
   PubMed Web of Science ®Google Scholar
• Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul. Immunol. Inflamm. 20(2), 86–90 (2012).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm. World Sci. 27(6), 423–431 (2005).
   PubMedGoogle Scholar
• Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann. Rheum. Dis. 71(5), 753–760 (2012).
   PubMed Web of Science ®Google Scholar
• Ozçimen AA, Dilek K, Bingöl U et al. IL-1 cluster gene polymorphisms in Turkish patients with Behçet’s disease. Int. J. Immunogenet. 38(4), 295–301 (2011).
   PubMedGoogle Scholar
• Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br. J. Ophthalmol. 91(2), 263–264 (2007).
   PubMed Web of Science ®Google Scholar
• Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, Sève P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. doi:10.1016/j.jbspin.2013.03.004 (2013) (Epub ahead of print).
   PubMedGoogle Scholar
• Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br. J. Dermatol. doi:10.1111/bjd.12548 (2013) (Epub ahead of print).
   Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res. Ther. 15(3), R64 (2013).
   PubMed Web of Science ®Google Scholar
• Church LD, McDermott MF. Canakinumab, a fully-humanmAb against IL-1beta for the potential treatment of inflammatory disorders. Curr. Opin. Mol. Ther. 11, 81–89 (2009).
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367(25), 2396–2406 (2012).
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann. Rheum. Dis. 71(9), 1589–1591 (2012).
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin. Exp. Rheumatol. 30(3 Suppl. 72), S115 (2012).
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1b. J. Mol. Biol. 425(1), 94–111 (2013).
   PubMed Web of Science ®Google Scholar
• [No authorslisted] Deal watch: XOMA and Servier to develop anti-IL-1b antibody for inflammatory diseases. Nat. Rev. Drug Discov. 10(3), 166 (2011).
   Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1b-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann. Rheum. Dis. 71(4), 563–566 (2012).
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. ClinImmunol. 27(1), 1–18 (2007).
   Google Scholar
• Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 91(10), 1341–1344 (2007).
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5), 764–770 (2005).
   PubMed Web of Science ®Google Scholar
• Wroblewski K, Sen HN, Yeh S et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can. J. Ophthalmol. 46(4), 322–328 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N et al. Involvement of Th17 cells and the effect of anti-IL-6 Therapy in autoimmune uveitis. Rheumatology 48, 347–354 (2009).
   PubMed Web of Science ®Google Scholar
• Curnow SJ, Falciani F, Durrani OM et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest. Ophthalmol. Vis. Sci. 46, 4251–4259 (2005).
   PubMed Web of Science ®Google Scholar
• Hohki S, Ohguro N, Haruta H et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp. Eye Res. 91, 162–170 (2010).
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch. Clin. Exp. Ophthalmol. doi:10.1007/s00417-013-2436-y (2013) (Epub ahead of print).
   Google Scholar
• Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul. Immunol. Inflamm. 19, 382–383 (2011).
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab and effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J. Rheumatol. 39, 1294–1295 (2012).
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod. Rheumatol. 22(2), 298–302 (2012).
   PubMed Web of Science ®Google Scholar
• Adán A, Llorenç V, Mesquida M, Pelegrín L. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch. Clin. Exp. Ophthalmol. 251(9), 2249–2250 (2012).
   PubMedGoogle Scholar
• Blüml S, McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res. Ther. 15(Suppl. 1), S4 (2013).
   PubMed Web of Science ®Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 11, 88 (2013).
   PubMed Web of Science ®Google Scholar
• Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov. Med. 15(81), 93–100 (2013).
   PubMedGoogle Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin. Ophthalmol. 6, 1613–1618 (2012).
   PubMedGoogle Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 50(8), 1390–1394 (2011).
   PubMed Web of Science ®Google Scholar
• Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 52(6), 986–997 (2013).
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 249(2), 297–300 (2011).
   PubMed Web of Science ®Google Scholar
• Copland DA, Liu J, Schewitz-Bowers LP et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am. J. Pathol. 180(2), 672–681 (2012).
   PubMed Web of Science ®Google Scholar
• Zarbin MA, Jampol LM, Jager RD et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 120(7), 1432–1439 (2013).
   PubMed Web of Science ®Google Scholar
• Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78(9), 672–680 (2012).
   PubMed Web of Science ®Google Scholar
• Shen H, Xia LP, Lu J. Elevated levels of interleukin-27 and effect on production of interferon-g and interleukin-17 in patients with Behçet’s disease. Scand. J. Rheumatol. 42(1), 48–51 (2013).
   PubMed Web of Science ®Google Scholar
• Amadi-Obi A, Yu CR, Liu X et al. Th17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13(6), 711–718 (2007).
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120 (4), 777–787 (2013).
   PubMed Web of Science ®Google Scholar